FDA Will Summarily Deny Petitions Submitted Solely To Block ANDA Approvals

Blocking generic competition by using citizen petitions to delay abbreviated new drug application approvals just got harder, under an FDA draft guidance released Jan. 16

More from Archive

More from Pink Sheet